 The second site is the world leader in retinal prosthetics. These are electronic implants and glasses that restore vision to blind patients. The Argus II retinal prosthesis is the only device approved by the FDA for restoring vision to the blind and is a result of over 20 years in development and over $200 million in private and public investment. These are the glasses that the patients actually wear. In the center you can see there's a small video camera that picks up the signal in front of the patients. That signal is then wirelessly transmitted by this coil to an implant in and around the eye. That implant electrically stimulates the retina at the back of the eye and produces a perception of vision, thus restoring vision to these blind patients. I think Edison got it right and famously said that innovation is 99% perspiration and 1% inspiration. As our team developed the Argus II retinal prosthesis over the last 20 plus years, there were certainly many aha moments of creative inspiration, but the vast majority of the time was working through the many problems that arose and staying focused on the problems that really mattered. Another key characteristic of a successful innovator is persistence. There were many near-death experiences along the way where it seemed like we had hit an insurmountable problem, the proverbial brick wall, but each time we pushed through. Blindness is one of the most feared disabilities. Each of us can imagine what is likely blind simply by closing our eyes, for the first time in history is a treatment for profoundly blind patients. We've opened a window for these patients back into the seeing world that most of us live in and most of us take for granted. Patients receiving the Argus II can perform tasks that previously blind individuals couldn't even dream of performing. They can locate doors and windows, they can follow a crosswalk in the street, they can avoid obstacles in their path, and the best performing patients can even read large letters and words. Today, we have a product that treats a specific type of blindness, red night is pigmentosa. We have clinical trials planned to expand the use of that product to patients with macular degeneration and even have plans for a new device that could restore vision to patients with blindness from all causes, which could help 8 million people globally.